EPI

WorkForce Software Announces Partner Excellence Award Winners EPI-USE, Accenture, and SAP SuccessFactors for their Commitment to Shaping the Future of Work Through Modern Workforce Management Technology

Retrieved on: 
Dienstag, Mai 2, 2023
Workforce, EPI, Senior, Education, Health, SAP SuccessFactors, Software, SAP, Channel partner, Public sector, Accenture, Partner, Mining, HR, Partnership, Growth, Conference, Utility, Asset management, Management

LIVONIA, Mich., May 2, 2023 /PRNewswire/ -- Today, the first global provider of integrated employee experience and workforce management solutions WorkForce Software, announces the winners of its 2023 Partner Excellence Awards. These awards recognize partners who have demonstrated exceptional value to global employers committed to modernizing their workforce management capabilities. The awards were announced at WorkForce Software's VISION 2023 Essentials Conference in Nashville, Tennessee. VISION is a gathering of industry experts, HR leaders, operations professionals, and WorkForce Software's global partners, where they discuss the critical importance of harnessing data and the latest technologies to enhance operational outcomes and provide a better work experience for employees, particularly for the deskless workers who make up a significant portion of the workforce.

Key Points: 
  • WorkForce Software has recognized EPI-USE, Accenture, and SAP SuccessFactors with the 2023 Partner Excellence Awards for their unwavering dedication to providing workforce management solutions to customers leveraging WorkForce Software's solutions.
  • LIVONIA, Mich., May 2, 2023 /PRNewswire/ -- Today, the first global provider of integrated employee experience and workforce management solutions WorkForce Software , announces the winners of its 2023 Partner Excellence Awards.
  • The 2023 WorkForce Software Partner Excellence Awards recognizes achievement in the areas of Partner Innovation, Global Systems Integration, and Business Partnership.
  • Their continued growth and investment in their WorkForce Software practice have made them a strategic systems integrator within the WorkForce Software partner ecosystem.

Mediso launches next generation MRI spectrometer spinScan®

Retrieved on: 
Dienstag, April 25, 2023
Sequence, Workflow, Digital cross-connect system, MRI, EPI, OEM, FDA, Acquisition, Mediso, Research, FPGA, Medical imaging

BUDAPEST, Hungary, April 25, 2023 /PRNewswire/ -- Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line.

Key Points: 
  • BUDAPEST, Hungary, April 25, 2023 /PRNewswire/ -- Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line.
  • The new spectrometer was optimized for MRI applications delivering an ultra-low-noise expandable RF front-end and real-time dynamic shimming.
  • The spectrometer is interfaced with three Mediso developed software applications to deliver a complete MRI workflow: the Sequence Development Platform for absolute control over the pulse sequences and reconstruction algorithms, the FDA approved and clinically validated InterView™ FUSION and Nucline™ for routine acquisition planning, reconstruction, image post-processing and evaluation.
  • Gergő Bagaméry, Director of Preclinical Product Development at Mediso commented: "Our main goal was to have a dedicated MRI spectrometer that is optimized for image quality, and works seamlessly with our clinically validated software platforms.

First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

Retrieved on: 
Dienstag, April 25, 2023
EPI, CFA, Exocrine pancreatic insufficiency, Clinical trial, BOCA, First wave, CNA, Patient, Cystic fibrosis, SPAN, CFA Training College, Safety, Malabsorption, Pharmaceutical industry

The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.

Key Points: 
  • The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.
  • James Sapirstein, Chief Executive Officer of First Wave BioPharma, commented, “We are very pleased to have reached the half-way mark of enrollment in our SPAN study of adrulipase.
  • This represents an important milestone for First Wave and demonstrates that we are on track to complete enrollment in 1H’23 and report topline data in July 2023.
  • The SPAN trial is an open-label study that will be conducted at three sites in the U.S. A total of 12 cystic fibrosis patients, 18 years or older are expected to be enrolled.

Mediso launches next generation MRI spectrometer spinScan®

Retrieved on: 
Dienstag, April 25, 2023
Sequence, Workflow, Digital cross-connect system, MRI, EPI, OEM, FDA, Acquisition, Mediso, Research, FPGA, Medical imaging

BUDAPEST, Hungary, April 25, 2023 /PRNewswire/ -- Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line.

Key Points: 
  • BUDAPEST, Hungary, April 25, 2023 /PRNewswire/ -- Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line.
  • The new spectrometer was optimized for MRI applications delivering an ultra-low-noise expandable RF front-end and real-time dynamic shimming.
  • The spectrometer is interfaced with three Mediso developed software applications to deliver a complete MRI workflow: the Sequence Development Platform for absolute control over the pulse sequences and reconstruction algorithms, the FDA approved and clinically validated InterView™ FUSION and Nucline™ for routine acquisition planning, reconstruction, image post-processing and evaluation.
  • Gergő Bagaméry, Director of Preclinical Product Development at Mediso commented: "Our main goal was to have a dedicated MRI spectrometer that is optimized for image quality, and works seamlessly with our clinically validated software platforms.

EPI-USE signs Strategic Collaboration Agreement with AWS to accelerate Cloud migrations for organizations using SAP

Retrieved on: 
Donnerstag, April 20, 2023
Networks, IOT (Internet of Things), Data Management, Technology, Software, EPI, Microsoft Partner Network, Microsoft Windows, SAP, SCA, AWS, Organization, City, SAP ERP, Growth, Maple syrup, Kubernetes

In pursuit of a prodigious increase in SAP migrations to AWS , EPI-USE and AWS will benefit from joint investments over the next 5 years under the new SCA.

Key Points: 
  • In pursuit of a prodigious increase in SAP migrations to AWS , EPI-USE and AWS will benefit from joint investments over the next 5 years under the new SCA.
  • Initially, the focus will be on migrating SAP workloads to AWS to augment EPI-USE’s existing Windows on AWS, Mendix on AWS, and Kubernetes service areas.
  • Under the SCA, EPI-USE Labs’ suite of proprietary SAP-related software utilities , already licensed to over 1200 organizations using SAP worldwide, will be harnessed to dramatically simplify, de-risk and accelerate migration of SAP systems to AWS.
  • We support our customers cloud and modernization journey, with SAP initiatives and strategies that expedite digital transformation and drive success.”

Olympus Launches EndoClot Hemostatic Agents and Submucosal Injection Agent in European Markets

Retrieved on: 
Donnerstag, April 20, 2023
ECA, Partnership, EPI, PHS, SIS, Olympus, Teaching hospital, Gent, ESD, Pharmaceutical industry

HAMBURG, Germany, April 20, 2023 /PRNewswire/ -- Olympus today announced the launch of EndoClot® Adhesive (ECA), EndoClot® Polysaccharide Hemostatic Spray (PHS) and EndoClot® Submucosal Injection Solution (SIS) in the Europe, Middle East and Africa (EMEA) region. This innovative portfolio is developed by EndoClot Plus, Inc. (EPI), which expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.

Key Points: 
  • HAMBURG, Germany, April 20, 2023 /PRNewswire/ -- Olympus today announced the launch of EndoClot® Adhesive (ECA), EndoClot® Polysaccharide Hemostatic Spray (PHS) and EndoClot® Submucosal Injection Solution (SIS) in the Europe, Middle East and Africa (EMEA) region.
  • This innovative portfolio is developed by EndoClot Plus, Inc. (EPI), which expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.
  • "We are excited to expand our global partnership with EndoClot Plus, Inc.
  • By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard or care."

Transphorm at PCIM 2023: Superior GaN Solutions Powering Electric Vehicle Systems to Adapters

Retrieved on: 
Mittwoch, April 19, 2023
Semiconductor, Engineering, Automotive Manufacturing, Technology, Manufacturing, Hardware, EPI, Renewable resource, PD, FIT, SIP, APEC, Design for manufacturability, Industry Standard, Hall, TSMC, DSC, AEC, Silicon, FET, Gallium nitride, Video game, Transphorm, Designability

Devices on display will demonstrate Transphorm’s ability to support low to high power systems with GaN power conversion solutions offering unparalleled Manufacturability, Designability, Drivability, and Reliability.

Key Points: 
  • Devices on display will demonstrate Transphorm’s ability to support low to high power systems with GaN power conversion solutions offering unparalleled Manufacturability, Designability, Drivability, and Reliability.
  • And, at PCIM, Transphorm will again achieve a critical milestone by unveiling design resources for the 1200 V GaN device first demonstrated a year ago .
  • This device will complement the company’s already strong 650 V solutions enabling various electric vehicle applications.
  • Learn more about how Transphorm’s GaN platform impacts power systems across all power levels during the Bodo’s Power Systems session.

Electromedical Products International Forms Scientific Advisory Board

Retrieved on: 
Donnerstag, April 6, 2023
Neurology, Mental Health, Medical Devices, Health, Clinical Trials, SAB, Acute stress disorder, EPI, Depression, University, Deficit spending, United States Air Force Scientific Advisory Board, Chapel Hill, Department of Neurology, Xuanwu hospital, Research, Defence Bioengineering and Electromedical Laboratory, Mentorship, University of North Carolina at Pembroke, Biomedical engineering, Cell biology, Breakthrough and Milestones Productions International, Patient, Biomedicine, Jesse Russell, Transcranial magnetic stimulation, Chronic pain, Alpert Medical School, Anxiety, Physiology, Pharmaceutical industry, Medical device, Psychiatry

Electromedical Products International, Inc. (EPI), manufacturer of Alpha-Stim® technology , announced today the formation of its Scientific Advisory Board (SAB) comprising leading clinicians and researchers in neurology, psychiatry and neurostimulation.

Key Points: 
  • Electromedical Products International, Inc. (EPI), manufacturer of Alpha-Stim® technology , announced today the formation of its Scientific Advisory Board (SAB) comprising leading clinicians and researchers in neurology, psychiatry and neurostimulation.
  • The SAB will work closely with EPI’s leadership team to provide scientific and clinical input into the company’s clinical trials in non-invasive brain stimulation as well as potential expansion into additional therapeutic indications.
  • The SAB will also advise Pulvinar Neuro, a wholly owned subsidiary of EPI, on the development of its neurotechnology portfolio.
  • Dr. Frohlich has deep expertise in neurotechnology development, translational non-invasive brain stimulation research, and clinical trials in psychiatry and neurology.

Tired of Closed Captioning? New ZVOX Speaker Makes TV Dialogue Clear Using Patented Hearing Technology

Retrieved on: 
Mittwoch, April 5, 2023
QVC, Music, EPI, HSN, Walmart, Multimedia, Ohm's acoustic law, Tablet, Collection, Amazon (company), Hearing, Algorithm, MA, Kool-Aid, Bluetooth, Apple, Cambridge SoundWorks, Swampscott, Massachusetts, Best Buy, Mobile phone, Video game, Amazon

SWAMPSCOTT, Mass., April 5, 2023 /PRNewswire/ -- ZVOX, the world leader in voice clarifying technology, is introducing a new TV speaker to its acclaimed collection of dialogue-clarifying products. The compact AV120 AccuVoice TV Speaker with Bluetooth provides users with two levels of ZVOX's proprietary AccuVoice dialogue clarifying technology to "lift" TV dialogue out of background sounds, so users can hear every word – even at low volumes or during heavy action sequences. Specially priced at just $99.99, the AV120 is available in black or bronze on ZVOX.com, Amazon.com, Walmart.com, and other retailers.

Key Points: 
  • $99.99
    SWAMPSCOTT, Mass., April 5, 2023 /PRNewswire/ -- ZVOX , the world leader in voice clarifying technology, is introducing a new TV speaker to its acclaimed collection of dialogue-clarifying products.
  • The AV120's patented AccuVoice dialogue clarification system uses techniques developed by the hearing aid industry to make voices crisp and easy to understand.
  • With the launch of its first AccuVoice TV Speaker, ZVOX created a new category of dialogue clarifying soundbars, speakers, and headphones.
  • Today ZVOX offers a variety of hearing-related products including TV speakers, conference call speakers, wireless headphones, and hearing aids.

Novan Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, März 30, 2023
Rosacea, EPI, Satō, Drug development, SG, File, Marketing, Novin, NDA, Health, Nitric oxide, Research, Research and development, Development, Acquisition, Molluscum contagiosum, PDUFA, Webcast, SB206, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Pharmaceutical industry, Cryptocurrency, Video game, Dermatology

DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, March 30, 2023, at 8:30 a.m. ET (details below).

Key Points: 
  • ET –
    DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update.
  • As of December 31, 2022, Novan had a total cash and cash equivalents balance of $12.3 million.
  • Novan reported total revenue of $23.7 million and $3.0 million for the year ended December 31, 2022 and 2021, respectively.
  • 61% growth in 2022 compared to 2021;
    68% growth in fourth quarter 2022 compared to fourth quarter 2021; and
    13% decrease in fourth quarter 2022 compared to third quarter 2022.